Background: Dr Nelson's Improved Inhaler was first marketed with an advertisement
Introduction
Inhaled therapies have been used for the treatment of pulmonary conditions and psychotropic effects for well over 4,000 years, 1, 2 and the inhalation of vapours is documented in Egyptian, Indian, European, and East Asian texts. In the modern period, barring a few advocates, inhalation was a little-used route for administration of medicinal therapies until the early-19 th century. Inhalation became increasingly noted as a therapeutic form in the late-18 th century, first with Philip Stern advocating his own recipe of balsamic vapours in 1764, 3 then John Mudge's invention of a simple pewter inhaler in 1778 (seemingly the first use of the word 'inhaler' by a physician), 4 and finally Thomas Beddoes and Humphry Davy's experiments at the Pneumatic Institute in Bristol in the 1780s and 1790s. 2, 5 British (Victorian) physicianinventors were introduced to inhalation anaesthesia from Boston (US America) in 1846-47, which served likewise to normalize perceptions of inhaled medicines and accelerate the exploitation of new materials (e.g. rubber and basic plastics) from the empires. This also helped to industrialize the production of steam-based inhalers and pneumatic atomizers which were at that stage being developed across France, Germany and Britain. Increasingly steam-based inhalers were being used for treating diseases like bronchitis, croup, and catarrh that accompanied the transition to industrial and urban modes of living.
It was against this backdrop that the increasing awareness of pulmonary drug delivery in the medical press and the general demand for effective respiratory treatments congenially aligned in one of the least spectacular, but most successful Steam inhalers were replaced in conventional respiratory medicine by modern inhaler devices from the mid-20 th century. 13 However steam inhalations remained in popular use for ameliorating chronic bronchitis throughout the 20 th century, 14 and are recommended by healthcare practitioners across the world in the 21 st century. 15 
Dr
Nelson's inhaler is still produced today, although it is now more usually used by singing coaches and performers including Ella Henderson, Sam Smith, and Professor Green. [16] [17] [18] Vapour-steam inhalations are one of the most frequently selfprescribed products for those with asthma 19 as well as in other pulmonary conditions such as the common cold, although there is little available evidence to support this latter use. 20 Indeed the risks of burns and scalds when using steam inhalations may outweigh any therapeutic benefit. 21, 22 Steam inhalations were not universally trumpeted and the effectiveness of the formulae of the British Pharmacopoeia was questioned in the academic press at the time. 23 Hassall challenged the use of vapour inhalants based on meticulous experiments. In his critique he anticipated that there would be improvements to inhaler devices; however without the availability of modern analytical techniques, experimentation and device development were pragmatic and empirical. It is possible that the paucity of evidence for vapour inhalants arises from the poor quality Coinciding with the 150 th anniversary of Dr Nelson's Inhaler, the aim of this research was to examine whether an experimental history of science approach could offer evidence for the quality of historical therapies discounted by modern medicine. 24 The approach included applying modern pharmaceutical performance testing of vapour inhalants of relevance to both historical and contemporary respiratory therapies.
Methodology

Experimental history of science approach
The history of medical therapies focuses increasingly on the pragmatic and material dimensions of the subject, [25] [26] [27] using both literary (e.g. journal articles, patents etc.) and non-literary components in its understanding of medical history. Pharmacy has always been a practical, hands-on form of production, experimentation, and provision of medical therapy, and is an ideal field in which to promote the experimental history of science approach. In terms of a history of pharmaceutical therapies, this means combining traditional methods of historical analysis (including the theoretical and conceptual knowledge recorded in pharmacopoeia and formularies, advertisements, prescriptions, medical publications and contemporary literature or popular press) with the identification of the experimental capabilities of the time (e.g. available analytical techniques), and the nature of pharmaceutical materials themselves (i.e. therapeutic use, efficacy and side-effects). 28 For example, in one experimental approach medicines are reconstructed according to historical sources before being analysed according to current forms of analysis. 29 In this respect vapour inhalations represent an excellent case study, since several remedies are still widely available as over-the-counter products or as (nowregulated) herbal medicines of traditional use, which, although not allopathic, are still widely used in respiratory self-management.
A survey of historical literature and correspondences relating to Dr Nelson's Inhaler, the history of S. Maw and Sons, and clinical, commercial and advertising resources referring to the treatment of pulmonary diseases was conducted using online and print archival materials at the Bodleian Library, the Wellcome Library, the British Library, the Science Museum (London), and the BMJ Publishing Group Archives. The FSI was cooled with ice-packs for 30 min and maintained wrapped in ice-packs to prevent post-deposition evaporation of the volatile components. Rather than a continuous airflow, the 'inhalation' of a patient through the device was simulated using the Canadian Standard adult sinus breathing profile (500 mL tidal volume, 13 min -1 respiration rate, 1:2 inspiratory:expiratory ratio) for a 10 min test period. 30 The non-respirable and respirable doses of BA were determined by HPLC-UV, as above.
In the case of the FSI, the respirable dose is retained on a glass-fibre filter trap, and corresponds to an aerosol size below 5 µm.
Results
Historical evidence of quality for Dr Nelson's Inhaler
At the conclusion of a meeting of the Royal Medical and Chirurgical Society (RMCS) on May 28 th 1861, a certain Dr Nelson presented an inhaler (Figure 1 ), "its claims to notice being, great ease and simplicity of action; perfect cleanliness; and an arrangement of the mouthpiece by which is secured economy in the use of any medicated ingredient that may be required for inhalation". 6, 7 It is of interest that the presentation noted issues which remain of concern in modern inhalation therapy, namely the requirement for simplicity and ease of use by the patient to minimize errors of use. The inhaler was manufactured by Maw & Sons, a company at the forefront of manufacturing and supplying medical equipment to British hospitals and medical practitioners in Victorian Britain. Its reputation was such that it was featured in the 1862 Exhibition, 7 where coincidentally a range of its ceramic inhalers were displayed. 23 It is notable that the designs of Dr Nelson's Inhaler (Figures 1 and 2) lack many of the features which Hill Hassall criticised for the devices he tested, and device performance was also affected by the poor formulation design at the time.
Experimental examination of the functional performance of Dr Nelson's Inhaler
HPLC analysis of the Friars' Balsam revealed the content of benzoic acid (BA) in the proprietary product to be 10·64 ± 0·07 mg/mL of tincture (i.e. 1·06 % w/v). Therefore the total dose formulated as the steam inhalation was 35·11 ± 0·23 mg of BA. The twin stage impinger (TSI) contains a solvent trap to capture all aerosol which enters the apparatus. However, the performance testing revealed that only 130·8 ± 14·7 µg of BA was emitted from the Nelson's Inhaler into the TSI as an aerosol (i.e. ~ 0·37 % of the total available BA dose). The dose of BA with an aerosol size suitable for deposition in the lungs (i.e. < 6·4 µm) was 59·95 ± 9·00 µg following 10 min of simulated inhalation at 60 Lmin -1 . It is of note, that this corresponded to 45·7 ± 2·9 % of the total emitted aerosol.
BA was selected as an appropriate marker compound for further mechanistic study, since it was the only compound appearing in the Friars' Balsam HPLC-UV chromatograms that was also observed in the samples of aerosol depositing in the TSI. The deposition profile and performance metrics for steam aerosolization of the benzoic acid tincture are presented in Figure 3 . The respirable dose (fine particle dose in Figure 3 ) was higher following 10 min compared to 5 min of operation (p<0.05), however the respirable fraction was unaffected by the aerosolization airflow (p>0.05 for 5 min versus 10 min of operation). This indicted that the aerosolization process would be consistent between patients, consistently delivering a high fraction suitable for deposition in the lungs of the user (~45 %).
Operating the inhaler for 10 min at 60 Lmin -1 provided a statistically significant doubling of device efficiency and fine particle dose compared to 5 min operation, indicating that duration of inhalation and total inhaled volume are the key patient-use factors affecting the dose inhaler performance. Statistical analysis of the performance data (ANOVA and post-hoc Tukey's testing) demonstrated no difference between the emitted dose, device efficiency or fine particle dose for the 5 min (60 Lmin -1 ) and 10 min (sinus breathing) conditions, generally derived from the high variability in the simulated inhalation testing.
Discussion
This study sought to identify remedies employed during the age of the steam inhaler, on which basis, tincture of benzoin 33 was chosen due to its widespread use as an expectorant at this period. The most commonly available form of this particular therapy to emerge from our literature review was Friars' Balsam. 1, 34 It is interesting 
30.
Dolovich 18. Prof Green. 2013. @Jessie_Ware can't help you there but never, ever sing straight after steaming as you can rupture blood vessels! X.
List of Figure Legends
[twitter]. 6 Apr 2013.
Available from:
https://twitter.com/professorgreen/status/320654704768057344?lang=en-gb.
Accessed October 29, 2015 
